Olmesartan/Hydrochlorothiazide Aurobindo Pharma (Malta) (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Hydrochlorothiazide Aurobindo Pharma (Malta), is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional diuretic therapy. GNH USA supplies Olmesartan/Hydrochlorothiazide Aurobindo Pharma (Malta) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan/Hydrochlorothiazide Aurobindo Pharma (Malta) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Hydrochlorothiazide is indicated for the management of hypertension, acting on the renin‑angiotensin‑aldosterone system and promoting diuresis. - Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient. - Resistant hypertension: provides additional blood‑pressure control in patients not achieving targets with a single agent. - Edema associated with hypertension: reduces fluid retention through its thiazide component. - Cardiovascular risk reduction: contributes to long‑term risk management in hypertensive patients.

Common Side Effects: - Dizziness: mild to moderate light‑headedness, especially after the first dose. - Headache: transient cranial discomfort. - Fatigue: general tiredness not related to activity level. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Cough: occasional dry throat irritation. Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe electrolyte disturbances: marked hypokalemia or hyponatremia. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: elevated liver enzymes. - Severe hypotension: symptomatic low blood pressure. - Allergic skin reactions: rash, Stevens‑Johnson syndrome.

Before initiating therapy, evaluate renal function, electrolyte status, and blood pressure response. - Monitor blood pressure: ensure target levels are achieved without excessive drop. - Assess renal function: check serum creatinine and eGFR periodically. - Check electrolytes: especially potassium and sodium levels during treatment. - Avoid abrupt discontinuation: taper if therapy is stopped to prevent rebound hypertension. - Pregnancy and lactation: contraindicated in pregnancy; use only if benefits outweigh risks in breastfeeding. Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Olmesartan/Hydrochlorothiazide may interact with several drug classes, requiring clinical awareness. Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalaemia. - Lithium: increased lithium levels, potential toxicity. - Aliskiren (in diabetics): heightened risk of renal impairment and hypotension. Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - ACE inhibitors or ARBs: additive potassium rise, monitor serum levels. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.